CryoPort Inc (CYRX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:CryoPort Inc (CYRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013280
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cryoport Inc (Cryoport) is a provider of cold chain logistics solutions for temperature-sensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials related to the shipment. It also offers SmartPak II condition monitoring system that provides information regarding the shipment including pressure, light, orientation, location, temperature, humidity and shock. Cryoport provides logistics consulting regarding all aspects including supply chain optimization from the manufacturer to patient, staff training, software installation and site assessment. It offers services to biopharmaceutical institutions including contract manufacturers, labs, diagnostics, clinical trial centers; academic and research institutions; in-vitro fertility (IVF) industry and animal health market. Cryoport is headquartered in Irvine, California, the US.

CryoPort Inc (CYRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CryoPort Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CryoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
CryoPort Inc, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
Cryoport Raises USD12.7 Million in Public Offering of Shares 9
CryoPort Raises USD6.8 Million in Public Offering of Units 11
CryoPort Completes Third Tranche Of Private Placement Of Units For US$0.4 Million 13
CryoPort Completes First Round Of Private Placement For US$4.43 Million 14
Debt Offering 15
CryoPort Completes Private Placement Of Debt Securities For US$0.3 Million 15
CryoPort Inc – Key Competitors 16
CryoPort Inc – Key Employees 17
CryoPort Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Apr 11, 2016: Cryoport Announces Global Temperature Controlled Logistics Consulting Services 19
Jan 26, 2016: Cryoport Introduces Its Advanced Cryogenic Logistics Solutions for IVF to the Cambodia and Czech Republic Markets 21
Financial Announcements 22
Nov 02, 2017: Cryoport Revenue Up 52%; Driven by BioPharma 22
Aug 08, 2017: Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma 24
Mar 13, 2017: Cryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31, 2016 26
Nov 14, 2016: Cryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017 28
Aug 15, 2016: Cryoport Continues to Climb, Reporting 34% Revenue Growth for the First Quarter of Fiscal Year 2017 30
Jun 27, 2016: Cryoport Reports 50% Revenue Growth for Fiscal Year 2016 32
Feb 08, 2016: Cryoport Reports 50% Revenue Growth for the Third Quarter of Fiscal Year 2016 34
Government and Public Interest 35
Jun 07, 2017: Cryoport Expands Agreement with Sanaria to Support Grant Awards with U.S. National Institutes of Health and U.S. Army 35
Oct 25, 2016: Cryoport Supporting Over 100 Clinical Trials 36
Product News 37
Jun 20, 2016: Cryoport Launches Next Generation Condition Monitoring Technology 37
Other Significant Developments 38
Jan 17, 2017: Cryoport to Support ProMab Biotechnologies’ CAR-T Cell Preclinical Services 38
Sep 22, 2016: Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process 39
Aug 02, 2016: Cryoport to Support World-Leading Life Science Company’s Custom Development and Biologics Manufacturing Business 40
Jun 15, 2016: Cryoport Enters Bio-Storage Market 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
CryoPort Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CryoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CryoPort Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CryoPort Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CryoPort Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Cryoport Raises USD12.7 Million in Public Offering of Shares 9
CryoPort Raises USD6.8 Million in Public Offering of Units 11
CryoPort Completes Third Tranche Of Private Placement Of Units For US$0.4 Million 13
CryoPort Completes First Round Of Private Placement For US$4.43 Million 14
CryoPort Completes Private Placement Of Debt Securities For US$0.3 Million 15
CryoPort Inc, Key Competitors 16
CryoPort Inc, Key Employees 17
CryoPort Inc, Subsidiaries 18

★海外企業調査レポート[CryoPort Inc (CYRX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Asian Citrus Holdings Ltd (73):企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • MI Bioresearch Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary MI Bioresearch Inc (MI), formerly Molecular Imaging Inc, is a research institute that offers pharmacology research services. The institute offers services such as oncology pharmacology, immuno oncology, in vitro services, imaging and radiation. Its oncology pharmacology include subcutaneous …
  • Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma …
  • EIH Associated Hotels Ltd.:企業の戦略・SWOT・財務情報
    EIH Associated Hotels Ltd. - Strategy, SWOT and Corporate Finance Report Summary EIH Associated Hotels Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Biotec Pharmacon ASA (BIOTEC):医療機器:M&Aディール及び事業提携情報
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • Nanomix Inc-医療機器分野:企業M&A・提携分析
    Summary Nanomix Inc (Nanomix) is a medical device company that develops portable detection systems for point of care (POC) testing. The company provides Nanomix system, which is an automated system consisting a handheld reader and self-contained assay cartridge with a carbon nanotube biosensor. It p …
  • Development Center for Biotechnology:製薬・医療:M&Aディール及び事業提携情報
    Summary Development Center for Biotechnology (DCB) is a non profit organization that offers support to biotechnology and pharmaceutical companies. The organization develops biotech industry through its cooperation and industrialization, key technologies, infrastructure building, research and develop …
  • Hitachi Koki Co., Ltd.:企業の戦略的SWOT分析
    Hitachi Koki Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Samart Corporation Public Co Ltd (SAMART):企業の財務・戦略的SWOT分析
    Samart Corporation Public Co Ltd (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Canadian Natural Resources Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Canadian Natural Resources Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Canadian Natural Resources Ltd (Canadian Natural) is an independent upstream oil and gas company. The company carries out acquisition, exploration, development, production, marketing a …
  • Teva Pharmaceutical Industries Ltd (TEVA):企業の財務・戦略的SWOT分析
    Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Damac Real Estate Development Ltd
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Mack-Cali Realty Corp (CLI):企業の財務・戦略的SWOT分析
    Mack-Cali Realty Corp (CLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • EA Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary EA Pharma Co Ltd (EA Pharma), formerly Ajinomoto Pharmaceuticals Co Ltd, a subsidiary of Eisai Co Ltd, is a clinical research organization that develops, manufactures and sells pharmaceutical products. The organization develops pharmaceutical products based on amino acid-related technologies …
  • GeoVax Labs Inc (GOVX):製薬・医療:M&Aディール及び事業提携情報
    Summary GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus on HIV, Zika virus …
  • Italgas SpA-石油・ガス分野:企業M&A・提携分析
    Summary Italgas SpA (Italgas), a subsidiary of Snam SpA, is an oilfield service company that offers transportation and dispatching of natural gas, liquefied natural gas regasification, and storage and distribution of natural gas. The company's activities include rhino-analytical tests; instrumental …
  • Hexion Inc.:企業の戦略・SWOT・財務分析
    Hexion Inc. - Strategy, SWOT and Corporate Finance Report Summary Hexion Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ABB Ltd (ABBN)-エネルギー分野:企業M&A・提携分析
    Summary ABB Ltd. (ABB) is a provider of power and automation technologies. The company provides solutions for secure, energy-efficient generation, transmission and distribution of electricity and for increasing productivity in industrial, commercial and utility operations. ABB’s product and service …
  • Southern Co:発電所・企業SWOT分析
    Southern Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Circassia Group Plc (CIR):企業の財務・戦略的SWOT分析
    Circassia Group Plc (CIR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆